pacritinib
Commercial- Indications
- Myelofibrosis
Company intelligence / Profile preview
CTI BioPharma Corp.
Seattle, Washington, United Statessobi.com ↗
- Ownership
- Private
- Employees
- ~128
- Development stage
- Commercial
01
Overview
CTI BioPharma developed and commercialized VONJO (pacritinib), an oral kinase inhibitor approved by the FDA in February 2022 for the treatment of adult patients with myelofibrosis with severe thrombocytopenia.
- Therapeutic areas
- HematologyImmunologyOncology
- Modalities
- Small molecule drugsOral kinase inhibitors
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Teva Pharmaceutical Industries Ltd.S*BIO Pte Ltd.Baxalta
Beyond the preview
Go deeper on CTI BioPharma Corp..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTI BioPharma Corp..